Headlines about Peregrine Pharmaceuticals (NASDAQ:PPHM) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.4333777315513 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

PPHM has been the subject of several recent research reports. BidaskClub raised Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research downgraded Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. Noble Financial reaffirmed a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Monday, July 31st. Finally, ValuEngine downgraded Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.

Peregrine Pharmaceuticals (PPHM) traded down 4.77% on Tuesday, hitting $4.59. The stock had a trading volume of 200,158 shares. The stock’s market capitalization is $206.99 million. The company has a 50-day moving average price of $3.56 and a 200-day moving average price of $3.89. Peregrine Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $5.78.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its quarterly earnings data on Monday, September 11th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. The firm had revenue of $27.08 million during the quarter, compared to the consensus estimate of $15.22 million. Equities analysts predict that Peregrine Pharmaceuticals will post ($0.44) earnings per share for the current year.

In related news, Director Mark R. Bamforth acquired 50,000 shares of the stock in a transaction on Friday, October 27th. The stock was purchased at an average price of $4.50 per share, for a total transaction of $225,000.00. Following the completion of the transaction, the director now owns 200 shares of the company’s stock, valued at approximately $900. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://theolympiareport.com/2017/10/31/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-peregrine-pharmaceuticals-pphm-share-price.html.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Insider Buying and Selling by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.